Oxurion NV
XBRU:OXUR

Watchlist Manager
Oxurion NV Logo
Oxurion NV
XBRU:OXUR
Watchlist
Price: 0.2965 EUR Market Closed
Market Cap: 396.2k EUR
Have any thoughts about
Oxurion NV?
Write Note

Relative Value

The Relative Value of one OXUR stock under the Base Case scenario is 1.768 EUR. Compared to the current market price of 0.2965 EUR, Oxurion NV is Undervalued by 83%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

OXUR Relative Value
Base Case
1.768 EUR
Undervaluation 83%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
92
vs Industry
65
Median 3Y
125.8
Median 5Y
3 989.8
Industry
8.1
vs History
vs Industry
Median 3Y
-2.4
Median 5Y
-462.9
Industry
23
vs History
vs Industry
Median 3Y
-3.9
Median 5Y
-500.3
Industry
23.4
vs History
vs Industry
Median 3Y
-10.8
Median 5Y
-810.7
Industry
27.3
vs History
vs Industry
Median 3Y
-2.8
Median 5Y
-0.1
Industry
2.6
vs History
vs Industry
66
Median 3Y
126.6
Median 5Y
3 991.2
Industry
8.1
vs History
vs Industry
49
Median 3Y
559.9
Median 5Y
7 841.1
Industry
9.6
vs History
6
vs Industry
30
Median 3Y
-3.7
Median 5Y
-174.2
Industry
4.3
vs History
0
vs Industry
28
Median 3Y
-3.4
Median 5Y
-493.1
Industry
3.8
vs History
0
vs Industry
30
Median 3Y
-3.9
Median 5Y
-500.2
Industry
6
vs History
0
vs Industry
27
Median 3Y
-3.9
Median 5Y
-499.6
Industry
3.8
vs History
71
vs Industry
69
Median 3Y
22.4
Median 5Y
3 377.9
Industry
4.8

Multiples Across Competitors

OXUR Competitors Multiples
Oxurion NV Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
BE
Oxurion NV
XBRU:OXUR
396.2k EUR 1.5 -0 0.1 0.1
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 563 478.2 -178 533.6 -216 796.7 -214 322.8
US
Abbvie Inc
NYSE:ABBV
301B USD 5.4 59.2 14.8 22.8
US
Amgen Inc
NASDAQ:AMGN
162B USD 5 38.3 17.8 33.7
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
127.5B USD 12 -265.7 26.9 28.2
US
Gilead Sciences Inc
NASDAQ:GILD
115.4B USD 4.1 916 10.2 10.2
US
Epizyme Inc
F:EPE
94.1B EUR 1 875.5 -478.6 -521.2 -507.3
AU
CSL Ltd
ASX:CSL
138B AUD 6 33.9 20.9 26
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
88.6B USD 6.4 19 17.5 19.4
US
Seagen Inc
F:SGT
39.3B EUR 18.1 -55.4 -59.5 -53.7
NL
argenx SE
XBRU:ARGX
34.1B EUR 18.5 -129.9 -104.5 -76.1
P/E Multiple
Earnings Growth
BE
Oxurion NV
XBRU:OXUR
Average P/E: 213.3
Negative Multiple: -0
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -178 533.6 N/A
US
Abbvie Inc
NYSE:ABBV
59.2
412%
US
Amgen Inc
NASDAQ:AMGN
38.3
73%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -265.7
42%
US
Gilead Sciences Inc
NASDAQ:GILD
916
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -478.6 N/A
AU
CSL Ltd
ASX:CSL
33.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -55.4 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -129.9 N/A
EV/EBITDA Multiple
EBITDA Growth
BE
Oxurion NV
XBRU:OXUR
Average EV/EBITDA: 15.4
0.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 796.7 N/A
US
Abbvie Inc
NYSE:ABBV
14.8
28%
US
Amgen Inc
NASDAQ:AMGN
17.8
63%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
26.9
38%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -521.2 N/A
AU
CSL Ltd
ASX:CSL
20.9
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.5
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59.5 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -104.5 N/A
EV/EBIT Multiple
EBIT Growth
BE
Oxurion NV
XBRU:OXUR
Average EV/EBIT: 20.1
0.1
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -214 322.8 N/A
US
Abbvie Inc
NYSE:ABBV
22.8
88%
US
Amgen Inc
NASDAQ:AMGN
33.7
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
28.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
10.2
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -507.3 N/A
AU
CSL Ltd
ASX:CSL
26
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
19.4
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.7 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.1 N/A

See Also

Discover More
Back to Top